US Stock MarketDetailed Quotes
LUMO Lumos Pharma
- 4.415
- +0.045+1.03%
Close Nov 4 16:00 ET
- 4.415
- 0.0000.00%
Post 20:01 ET
38.18MMarket Cap-998P/E (TTM)
4.467High4.370Low43.84KVolume4.400Open4.370Pre Close194.75KTurnover0.75%Turnover RatioLossP/E (Static)8.65MShares4.57652wk High3.72P/B25.79MFloat Cap1.37052wk Low--Dividend TTM5.84MShs Float36.720Historical High--Div YieldTTM2.21%Amplitude1.370Historical Low4.442Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Lumos Pharma Stock Forum
Dow Jones· 3 mins ago
Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, i...
I'm holding a little. hope gradually 🛫✌️
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than tradit...
Lumos Pharma Inc: Outcome From End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial
AUSTIN, TX, April 18, 2024 (GLOBE NEWSWIRE) – Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented...
No comment yet